ID   Li-7
AC   CVCL_3840
SY   LI7; Li7; C-Li-7
DR   CLO; CLO_0050854
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 571
DR   BioSample; SAMN03470992
DR   BioSample; SAMN10987749
DR   cancercelllines; CVCL_3840
DR   CCRID; 1101HUM-PUMC000678
DR   CCRID; 3101HUMSCSP5062
DR   CCRID; 3101HUMTCHu183
DR   Cell_Model_Passport; SIDM01472
DR   CGH-DB; 9074-4
DR   CLS; 305102
DR   Cosmic; 721062
DR   Cosmic; 2023862
DR   Cosmic; 2162529
DR   Cosmic; 2771607
DR   DepMap; ACH-000471
DR   GEO; GSM565882
DR   GEO; GSM887266
DR   GEO; GSM888341
DR   GEO; GSM2551577
DR   IARC_TP53; 30113
DR   LiGeA; CCLE_219
DR   LIMORE; Li7
DR   PharmacoDB; Li7_835_2019
DR   PRIDE; PXD002486
DR   Progenetix; CVCL_3840
DR   RCB; RCB1941
DR   TKG; TKG 0368
DR   Wikidata; Q54902491
RX   PubMed=85491;
RX   PubMed=2542205;
RX   PubMed=12029633;
RX   PubMed=15767549;
RX   PubMed=22460905;
RX   PubMed=23887712;
RX   PubMed=25877200;
RX   PubMed=30784169;
RX   PubMed=30894373;
RX   PubMed=31063779;
RX   PubMed=31068700;
RX   PubMed=31378681;
RX   PubMed=37610679;
WW   https://lccl.zucmanlab.com/hcc/cellLines/Li7
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.93%; East Asian, North=80.68%; East Asian, South=17.95%; South Asian=0%; European, North=0.44%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): CCRID; PubMed=25877200; PubMed=31378681; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 16
ST   D19S433: 12,14
ST   D21S11: 30
ST   D2S1338: 17,19
ST   D3S1358: 15,16
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13,14
ST   FGA: 20
ST   Penta D: 10
ST   Penta E: 5
ST   TH01: 7
ST   TPOX: 8 (TKG)
ST   TPOX: 8,11 (CCRID; PubMed=25877200; PubMed=31378681; RCB)
ST   vWA: 16,19
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   PubMed=85491;
RA   Hirohashi S., Shimosato Y., Kameya T., Koide T., Mukojima T.,
RA   Taguchi Y., Kageyama K.;
RT   "Production of alpha-fetoprotein and normal serum proteins by
RT   xenotransplanted human hepatomas in relation to their growth and
RT   morphology.";
RL   Cancer Res. 39:1819-1828(1979).
//
RX   PubMed=2542205; DOI=10.1111/j.1349-7006.1989.tb02290.x;
RA   Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.;
RT   "Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in
RT   human hepatocellular carcinoma.";
RL   Jpn. J. Cancer Res. 80:196-199(1989).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=30784169; DOI=10.1111/cas.13978;
RA   Sato Y., Yamada T., Hiroyama T., Sudo K., Hasegawa N., Hyodo I.,
RA   Nakamura Y.;
RT   "A robust culture method for maintaining tumorigenic cancer stem cells
RT   in the hepatocellular carcinoma cell line Li-7.";
RL   Cancer Sci. 110:1644-1652(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//
RX   PubMed=37610679; DOI=10.1007/s13577-023-00967-7;
RA   Seyama Y., Sudo K., Hirose S., Hamano Y., Yamada T., Hiroyama T.,
RA   Sasaki R., Hirai M.Y., Hyodo I., Tsuchiya K., Nakamura Y.;
RT   "Identification of a gene set that maintains tumorigenicity of the
RT   hepatocellular carcinoma cell line Li-7.";
RL   Hum. Cell 36:2074-2086(2023).
//